Determination of paraoxonase (PON1) status requires more than genotyping

Citation
Rj. Richter et Ce. Furlong, Determination of paraoxonase (PON1) status requires more than genotyping, PHARMACOGEN, 9(6), 1999, pp. 745-753
Citations number
56
Categorie Soggetti
Pharmacology & Toxicology
Journal title
PHARMACOGENETICS
ISSN journal
0960314X → ACNP
Volume
9
Issue
6
Year of publication
1999
Pages
745 - 753
Database
ISI
SICI code
0960-314X(199912)9:6<745:DOP(SR>2.0.ZU;2-U
Abstract
Human serum paraoxonase (PON1) is associated with high density lipoprotein (HDL) particles. This enzyme is involved in the metabolism of oxidized lipi ds and also plays a major role in the metabolism and detoxication of insect icides processed through the cytochrome P450/PON1 pathway. An Arg/Gln (R/Q) substitution at position 192 determines a substrate dependent activity pol ymorphism, In addition to the effect of the amino acid substitution on rate s of hydrolysis of different substrates, there is a large interindividual v ariability in the amount of PON1 protein in sera that is stable over time, Recently, a number of reports based solely on PON1 genotyping have suggeste d that in some populations, the PON1(R192) allele may be a risk factor for coronary artery disease. Another report notes an increased risk of the PON1 (R192) allele for Parkinson's disease. We report here the development of a two-dimensional, microtitre plate reader-based enzyme analysis that provide s a high-throughput assessment of PON1 status. population distribution plot s of diazoxonase Versus paraoxonase activities provides PON1 phenotype and an accurate inference of PON1 genotype. Both are important parameters for d etermining an individual's PON1 status, The analysis also provides PON1 all ele frequencies for specific populations, Pharmacogenetics 9:745-753 (C) 19 99 Lippincott Williams & Wilkins.